Chargement en cours...

Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer

Vandetanib (ZD6474) became the first systemic agent to be approved for the treatment of metastatic or locally advanced medullary thyroid cancer. It was a proof of principle, because it is an orally bioavailable medication that targets the growth factors felt to be important in the pathogenesis of th...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Deshpande, Hari, Marler, Vicky, Sosa, Julie Ann
Format: Artigo
Langue:Inglês
Publié: Dove Medical Press 2011
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3255572/
https://ncbi.nlm.nih.gov/pubmed/22241953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S17422
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!